Abemaciclib, a small‐molecule inhibitor of CDK4 and CDK6, is approved by the Chinese National Medical Products Administration for use in combination with ET for the treatment of HR+/HER2− ABC based on data from MONARCH plus.4 Here, HR is linked to aneurysmal bone cyst.